This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bullrich, F. Articles by Croce, C. M. Search for Related Content PubMed PubMed Citation Articles by Bullrich, F. Articles by Croce, C. M.

Characterization of the 13q14 Tumor Suppressor Locus in CLL

Identification of ALT1, an Alternative Splice Variant of the LEU2 Gene¹

Department of Microbiology and Immunology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107 [F. B., H. F., G. C., H. M., M. N., Y. P., H. A., C. M. C.]; The Burnham Institute Cancer Research Center, La Jolla, California 92037 [J. C. R.]; Section of Leukemia, Division of Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030 [M. J. K.]; Department of Medicine, University of California San Diego, La Jolla, California 92093 [L. R., T. J. K.]; and The CLL Research Consortium [L. R., J. C. R., M. J. K., T. J. K., C. M. C.]

Chromosome 13q14 deletions constitute the most common genetic abnormality in chronic lymphocytic leukemia (CLL). To identify the putative tumor suppressor gene targeted by 13q14 genomic loss, we completely sequenced and characterized a segment of 790 kb at 13q14 spanning the minimal region of loss in CLL. Transcribed sequences in the region were identified through database homology searches and exon-prediction analysis. Two-hundred kb at the centromeric end of the sequence contain five CpG islands, three previously identified genes LEU5/RFP2, LEU2, and LEU1, seven of seven EST clusters composed of >10 ESTs, and a large number of predicted exons. Homology searches against the mouse EST database have allowed us to identify a highly conserved alternative first exon of the LEU2 gene, giving rise to a novel transcript, ALT1 (GenBank accession no. AF380424), which originates within a G+C region in the vicinity of the D13S272 marker. Two novel 3' exons of LEU2 were also identified and are present in both LEU2 and ALT1 transcripts. However, we have not identified any mutations in leukemia cases, or alterations in expression of mRNAs in the region, that might directly implicate these mRNAs in the pathology of CLL. The centromeric end of the sequence, where all reported genes are located, contains twice the expected amount of ALU repeats, whereas the telomeric end is LINE1 rich and contains four LINE1 elements longer than 4 kb, including two full-length LINE1 sequences. This feature of the sequence may favor the occurrence of chromosomal rearrangements and may confer instability to the region, resulting in deletions that may inactivate an as yet unidentified tumor suppressor.

This article has been cited by other articles:

				E. Salerno, B. J. Scaglione, F. D. Coffman, B. D. Brown, A. Baccarini, H. Fernandes, G. Marti, and E. S. Raveche Correcting miR-15a/16 genetic defect in New Zealand Black mouse model of CLL enhances drug sensitivity Mol. Cancer Ther., September 1, 2009; 8(9): 2684 - 2692. [Abstract] [Full Text] [PDF]

				P. Ouillette, H. Erba, L. Kujawski, M. Kaminski, K. Shedden, and S. N. Malek Integrated Genomic Profiling of Chronic Lymphocytic Leukemia Identifies Subtypes of Deletion 13q14 Cancer Res., February 15, 2008; 68(4): 1012 - 1021. [Abstract] [Full Text] [PDF]

				E. S. Raveche, E. Salerno, B. J. Scaglione, V. Manohar, F. Abbasi, Y.-C. Lin, T. Fredrickson, P. Landgraf, S. Ramachandra, K. Huppi, et al. Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice Blood, June 15, 2007; 109(12): 5079 - 5086. [Abstract] [Full Text] [PDF]

				D. Ng, O. Toure, M.-H. Wei, D. C. Arthur, F. Abbasi, L. Fontaine, G. E. Marti, J. F. Fraumeni Jr, L. R. Goldin, N. Caporaso, et al. Identification of a novel chromosome region, 13q21.33-q22.2, for susceptibility genes in familial chronic lymphocytic leukemia Blood, February 1, 2007; 109(3): 916 - 925. [Abstract] [Full Text] [PDF]

				F. Petrocca, D. Iliopoulos, H. R. Qin, M. S. Nicoloso, S. Yendamuri, S. E. Wojcik, M. Shimizu, G. Di Leva, A. Vecchione, F. Trapasso, et al. Alterations of the Tumor Suppressor Gene ARLTS1 in Ovarian Cancer Cancer Res., November 1, 2006; 66(21): 10287 - 10291. [Abstract] [Full Text] [PDF]

				G. A. Calin, F. Trapasso, M. Shimizu, C. D. Dumitru, S. Yendamuri, A. K. Godwin, M. Ferracin, G. Bernardi, D. Chatterjee, G. Baldassarre, et al. Familial Cancer Associated with a Polymorphism in ARLTS1 N. Engl. J. Med., April 21, 2005; 352(16): 1667 - 1676. [Abstract] [Full Text] [PDF]

				M. LAGOS-QUINTANA, R. RAUHUT, J. MEYER, A. BORKHARDT, and T. TUSCHL New microRNAs from mouse and human RNA, February 1, 2003; 9(2): 175 - 179. [Abstract] [Full Text] [PDF]

				G. A. Calin, C. D. Dumitru, M. Shimizu, R. Bichi, S. Zupo, E. Noch, H. Aldler, S. Rattan, M. Keating, K. Rai, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia PNAS, November 26, 2002; 99(24): 15524 - 15529. [Abstract] [Full Text] [PDF]

				U. Novak, E. Oppliger Leibundgut, J. Hager, D. Muhlematter, M. Jotterand, C. Besse, N. Leupin, D. Ratschiller, J. Papp, G. Kearsey, et al. A high-resolution allelotype of B-cell chronic lymphocytic leukemia (B-CLL) Blood, August 13, 2002; 100(5): 1787 - 1794. [Abstract] [Full Text] [PDF]